Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline mutation or with BRCAPro scores

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2017-10, Vol.8 (45), p.79175-79187
Hauptverfasser:	Lee, Jung-Min, Hays, John L, Chiou, Victoria L, Annunziata, Christina M, Swisher, Elizabeth M, Harrell, Maria I, Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M, Ji, Jiuping, Figg, William D, Minasian, Lori, Lipkowitz, Stanley, Wood, Bradford J, Doroshow, James, Kohn, Elise C
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Research Paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline mutation or with BRCAPro scores
ISSN:	1949-2553 1949-2553
DOI:	10.18632/oncotarget.16577